ARA-290
An erythropoietin-derived peptide fragment studied for tissue-protective and neuropathy-related applications without the red-blood-cell effects of full EPO.
Also referenced as: Cibinetide
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when ARA-290 crosses your target, drops, or sets a new tracked low—without daily noise.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Cibinetide
No FDA label signal · 4 trials · 79 PubMed results
ARA-290 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
ARA-290 has 3 name-matched clinical trials (1 international) (highest phase: Phase 2) and 79 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results. Note: 2 retracted publications in the literature.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What ARA-290 is
ARA-290 is a small peptide derived from the tissue-protective region of erythropoietin. It is usually discussed as a way to explore anti-inflammatory and repair-oriented signaling without using full erythropoietin as a drug.
Why it matters
It shows up in the peptide market because it sits at the intersection of pain, small-fiber neuropathy, and tissue recovery. That gives it a very different profile from the more common tendon-and-muscle repair peptides.
Regulatory context
ARA-290 is not an FDA-approved therapy in the United States. It is best understood as an investigational compound with a more clinical backstory than many research-market entries.
Practical reading note
When this compound appears in vendor catalogs, the important distinction is that investigational interest does not equal routine clinical availability.